Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules
US11305015B2 · kind B2 · utility
0Cited by
23References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 26, 2019 |
| Grant date | Apr 19, 2022 |
| Priority date | — |
| Expiry date | Nov 26, 2039 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
CMV vectors that lack active UL128, UL130, UL146 and UL147 proteins that may also comprise one or more microRNA regulatory elements (MRE) that restrict expression of the CMV are provided. Immunization with CMV vectors having the described features allows selection of different CD8+ T cell responses—CD8+ T cells restricted by MHC-Ia, MHC-II, or by MHC-E.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.